Press coverage about St Jude Medical (NYSE:STJ) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. St Jude Medical earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical technology company an impact score of 46.9574999448976 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of STJ stock remained flat at $$80.82 during trading on Tuesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.93 and a quick ratio of 1.31. St Jude Medical has a 52 week low of $48.83 and a 52 week high of $84.00.

About St Jude Medical

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

See Also: Earnings Per Share (EPS)

Insider Buying and Selling by Quarter for St Jude Medical (NYSE:STJ)

Receive News & Ratings for St Jude Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for St Jude Medical and related companies with MarketBeat.com's FREE daily email newsletter.